Cardiovascular metabolic syndrome - An interplay of, obesity, inflammation, diabetes and coronary heart disease

Diabetes, Obesity and Metabolism

Volumn 9, Issue 3, 2007, Pages 218-232

  Rana, J S ^a   Nieuwdorp, M ^a   Jukema, J W ^b   Kastelein, J J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Diabetes; Inflammation; Metabolic syndrome; Obesity

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CREATININE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; ROSIGLITAZONE; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR METABOLIC SYNDROME; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLYCOCALYX; HEART INFARCTION; HEART MUSCLE; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 33947706245     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00594.x     Document Type: Review

References (114)

1. Leonard WR. Food for thought. Dietary change was a driving force in human evolution. Sci Am 2002; 287: 106-115.
2. World Health Organization. The World Health Report 2003 - Shaping the Future. Geneva, Switzerland: World Health Organization, 2003.
3. Murray CJL, Lopez AD. The Global Burden of Disease. Boston, Mass: Harvard School of Public Health, 1996.
4. Leeder S, Raymond S, Greenberg H, Liu H, Esson K. A Race Against Time. The Challenge of Cardiovascular Disease in Developing Economies. New York, NY: Columbia University, 2004.
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
6. Frenk J, Bobadilla JL, Sepulveda J, Cervantes LM. Health transition in middle-income countries: New challenges for health care. H Policy Plann 1989; 4: 29-39.
7. World Health Organization. Obesity: Preventing and managing the global epidemic - report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: 1-253.
8. Hubert HB, Feinleib M, McNamara PM et al. Obesity as an independent risk factor for cardiovascular disease: A 26 year follow up of participants in the Framingham heart study. Circulation 1983; 67: 968-976.
9. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body mass index and mortality cohort of US adults. N Engl J Med 1999; 341: 1097-1105.
10. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002; 106: 143-160.
11. Howard BV, Rodriguez BL, Bennett PH et al. Prevention conference VI. Diabetes and cardiovascular disease, writing group I: Epidemiology. Circulation 2002; 105: E132-e137.
12. King H, Aubert RE, Herman WH. Global burden of type 2 diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
13. Miettinen H, Lehto S, Salomaa V et al. for the FINMONICA Myocardial Infarction Register Study Group. Impact of type 2 diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21: 69-75.
14. Mokdad AH, Ford ES, Bowman BA et al. Type 2 diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000; 23: 1278-1283.
15. Vague J. The degree of masculine differentiation of obesity: A factor determining predisposition to diabetes, arteriosclerosis, gout and uric calculus disease. Am J Clin Nutr 1956; 4: 20-34.
16. Reaven GM. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 1993; 44: 121-131.
17. Dunstan DW, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance. The Australian diabetes, obesity and lifestyle study. Diabetes Care 2002; 25: 829-834.
18. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
19. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation 1999.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
21. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome (http://www.idf.org/webdata/docs/ Metac_syndrome_def.pdf) (14 April 2005) (accessed 15 May 2005).
22. Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
23. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome. Lancet 2005; 366: 1921-1922.
24. Gotto AM Jr, Blackburn GL, Dailey GE III et al. The metabolic syndrome: a call to action. Coron Artery Dis 2006; 17: 77-80.
25. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 14: 115-126.
26. Smith SC Jr, Anderson JL, Cannon RO III et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to Clinical and Public Health Practice: Report from the clinical practice discussion group. Circulation 2004; 110: E550-553.
27. Margolis KL, Manson JE, Greenland P et al. Women's Health Initiative Research Group. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: The Women's Health Initiative Observational Study. Arch Intern Med 2005; 165: 500-508.
28. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
29. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-372.
30. Mauriello A, Sangiorgi G, Fratoni S et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: A histopathologic study of patients dying of acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1585-1593.
31. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and type 2 diabetes. Trends Immunol 2004; 25: 4-7.
32. Haffner SM. Insulin resistance, inflammation and the prediabetic state. Am J Cardiol 2003; 92: 18J-26J.
33. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflugers Arch 2000; 440: 653-666.
34. van Haaren PM, van Bavel E, Vink H, Spaan JA. Localization of the permeability barrier to solutes in isolated arteries by confocal microscopy. Am J Physiol 2003; 285: H2848-H2856.
35. Van den Berg B, Vink H, Spaan JA. The endothelial cell glycocalyx protects against myocardial edema. Circ Res 2003; 92: 592-594.
36. Van den Berg B, Spaan JA, Vink H. Loss of endothelial glycocalyx precedes atherogenic laesion and carotid plaque formation. Am J Physiol 2005.
37. Constantinescu AA, Vink H, Spaan JA. Endothelial cell glycocalyx modulates immobilization of leucocytes at the endothelial surface. Arterioscl Thromb Vasc Biol 2003; 23: 1541-1547.
38. Mochizuki S, Vink H, Hiramatsu O et al. Role of hyaluronic acid in shear induced endothelium derived nitric oxide release. Am J Physiol 2003; 285: H722-H726.
39. Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer: Implications for platelet-endothelial cell adhesion. Circulation 2000; 101: 1500-1502.
40. Henry CB, Duling BR. TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 2000; 279: H2815-H2823.
41. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
42. Nieuwdorp M, van Haeften TW, Mooij HL et al. Endothelial Glycocalyx Perturbation During Acute Hyperglycemia Leads to Endothelial Dysfunction and Coagulation in Humans. Diabetes 2006; 55: 480-486.
43. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283: E413-E422.
44. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH (2) -terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-9054.
45. Waeber G, Delplanque J, Bonny C et al. The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes. Nat Genet 2000; 24: 291-295.
46. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332.
47. Brun RP, Tontonoz P, Forman BM et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 1996; 10: 974-984.
48. Johannsson G, Karlsson C, Lonn L et al. Serum leptin concentration and insulin sensitivity in men with abdominal obesity. Obes Res 1998; 6: 416-421.
49. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003; 9: RA55-RA61.
50. Kern PA, Ranganthan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751.
51. Kubaszek A, Pihlajamaki J, Komarovski V et al. Promoter polymorphisms of the TNF-a (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 type 2 diabetes: The Finnish type 2 diabetes prevention study. Diabetes 2003; 52: 1872-1876.
52. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adiposespecific protein, adiponectin, in type 2 diabetic patients. Arterioscler Throm Vasc Biol 2000; 20: 1595-1599.
53. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-981.
54. Duncan BB, Schmidt MI, Pankow JS et al. Adiponectin and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes 2004; 53: 2473-2478.
55. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. Novel interactions of Adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003; 88: 2714-2718.
56. Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-974.
57. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
58. Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity. Curr Atheroscler Rep 2004; 6: 424-431.
59. Bloomgarden ZT. Insulin resistance: Current concepts. Clin Ther 1998; 20: 216-231.
60. Kahn SE, Prigeon RL, McCulloch DK et al. Quantification of the relationship between insulin-sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42: 1663-1672.
61. Unger RH. Minireview: Weapons of Tean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144: 5159-5165.
62. Tooke JE. Microvascular function in human type 2 diabetes. A physiological perspective. Diabetes 1995; 44: 721-726.
63. Newman AB, Siscovick DS, Manolio TA et al. for the Cardiovascular Heart Study (CHS) Collaborative Research Group. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Circulation 1993; 88: 837-845.
64. Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care 2003; 26: 1922-1926.
65. Hopfner RL, Gopalakrishnan V. Endothelin: Emerging role in diabetic vascular complications. Diabetologia 1999; 42: 1383-1394.
66. Tesfamariam B, Brown ML, Deykin D, Cohen RA. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest 1990; 85: 929-932.
67. Grassi G, Dell'Oro R, Facchini A, Trevano FQ, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens 2004; 22: 2363-2369.
68. Grassi G, Dell'Oro R, Quarti-Trevano F et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359-1365.
69. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70-75.
70. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
71. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2005; 24: 278-301.
72. Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham study. JAMA 1979; 241: 2035-2038.
73. Von Eckardstein A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 2000; 85: 3101-3108.
74. UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care 1997; 20: 1683-1687.
75. Austin MA, Edwards KL. Small, dense low-density lipoproteins, the insulin resistance syndrome and non-insulin-dependent diabetes. Curr Opin Lipidol 1996; 7: 167-171.
76. Taskinen M-R. Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia 2003; 46: 733-749.
77. Carmena R, Betteridge DJ. Statins and diabetes. Semin Vasc Med 2004; 4: 321-332.
78. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Executive summary. Eur Heart J 2003; 24: 1601-1610.
79. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
80. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-1080.
81. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
82. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
83. Van Wijk JPHEJ, Pde Koning Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-1749.
84. Li AC, Binder CJ, Gutierrez A et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004; 114: 1564-1576.
85. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004; 21: 810-817.
86. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
87. Marx N, Froehlich J, Siam L et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.
88. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001; 86: 1306-1312.
89. Dormandy JA, Charbonnel B, Eckland DJ et al. the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289.
90. Erdmann E. The effect of Pioglitazone on Recurrent Myocardial Infarction in 2445 Patients With Type 2 Diabetes and Preexisting Myocardial Infarction -Data from the PROactive Study. Program and abstracts from the American Heart Association 2005 Scientific Sessions, Dallas, Texas. Late Breaking Clinical Trials IV 2005.
91. Sobel BE, Frye R, Detre KM; Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003; 107: 636-642.
92. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005; 48: 1726-1735.
93. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
94. Robins SJ, Rubins HB, Faas HF et al. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003; 26: 1513-1517.
95. Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki heart study. JAMA 1988; 260: 641-651.
96. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
97. Tenenbaum A, Motro M, Fisman EZ et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005; 165: 1154-1160.
98. Keech A, Simes RJ, Barter P et al. Effect of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): A randomised controlled trial. Lancet 2005; 366: 1849-1861.
99. Guyton JR, Blazing MA, Hagar J et al. Extended-release nicotinic acid vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160: 1177-1184.
100. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003; 171: 87-96.
101. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15: 659-665.
102. Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278: 9869-9874.
103. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
104. Canner P, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: Results from the Coronary Drug Project. Circulation 2002; 106 (Suppl. II): 3138 [abstract].
105. Wolfe ML, Vartanian SF, Ross JL et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001; 87: 476-479.
106. Insull W Jr, McGovern ME, Schrott H et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: Assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004; 164: 1121-1127.
107. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-1592.
108. Zhao X-Q, Morse J, Chait A et al. Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. J Am Coll Cardiol 2002; 39 (Suppl. A): 242A, 1130-1173 [abstract].
109. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: A randomized trial. JAMA 2000; 284: 1263-1270.
110. van der Steeg WA, Kuivenhoven JA, Klerkx AH, Boekholdt SM, Hovingh GK, Kastelein JJ. Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol 2004; 15: 631-636.
111. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S; RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397.
112. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases. overcoming impediments to prevention and control. JAMA 2004; 291: 2616-2622.
113. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 23: 2694-2703.
114. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. Prev Cardiol 2005; 8: 47-54.